Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy

NCT07440901 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Muscle-invasive Bladder Cancer

Interventions

DRUG: Immunotherapy plus chemotherapy

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences